Shanghai Kaibao Pharmaceutical Co LtdSHE 300039 Stock Report

Shanghai Kaibao Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of Chinese medicine. The company is headquartered in Shanghai, Shanghai and currently employs 1,432 full-time employees. The company went IPO on 2010-01-08. is a China-based company principally engaged in the research, development, manufacture and distribution of Chinese patent drugs. The firm's main product is Tanreqing injection, which is used for treatment of upper respiratory tract infections, such as cold and pneumonia. The firm's products include injections, tablets, capsules, granules, vinum and pills, among others. The firm distributes its products in domestic markets.